[1]
|
S. Robert, S. M. Gottlieb, M. H.
Schanker, D. Joel, D. O.
Weisman, F. P. Thim, A. R.
Wolf and S. Andrew, “Pnuemocystiscarinii
Pnuemoniaand Mucosal Candidiasis in
Previously Healthy Homosexual
Men—Evidence of a new Acquire Cellular Immunodeficiency,” New England
Journal of Medicine,
Vol. 305, 1981, pp. 1425-1431. http://dx.doi.org
/10.1056
/NEJM198112103052401
|
[2]
|
UNAIDS, “State of the Epidemic,” Report of the Global AIDS Epidemic, 2012, pp. 1-103. http://www.unaids.org
/en/media/unaids/contentassets
/documents/epidemiology/2012/gr2012
/20121120_UNAIDS_Global_Report_
2012_with_annexes_en.pdf
|
[3]
|
FMOH, “National HIV Sero-Prevalence Sentinel Survey among Pregnant Women Attending Antenatal Clinics in Nigeriam,” Technical Report, 2010, pp. 1-96.
|
[4]
|
S. M. Hammer, J. J. Eron Jr., P. Reiss, et al., “Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel,” JAMA, Vol. 300, No. 5, 2008, pp. 555-570. http://dx.doi.org/10.1001/jama.300.5.555
|
[5]
|
World Health Organization, UNAIDS and UNICEF, “Towards Universal Assess: Scaling up Priority HIV/AIDS Interventions in the Health Sector,” 2010.
|
[6]
|
G. Panos, G. Samonis, V. G. Alexiou, G. A. Kavarnou, G. Charatsis and M. E. Falagas, “Mortality and Mobidity of HIV-Infected Patients Receiving HAART: A Cohort Study,” Current HIV Research, Vol. 6, No. 3, 2008, pp. 257-260. http://dx.doi.org/10.2174/157016208784324976
|
[7]
|
P. Severe, P. Leger, M. Charles, et al., “Antiretroviral Therapy in a Thousand Patients with AIDS in Haiti,” New England Journal of Medicine, Vol. 353, No. 32, 2005, pp. 2325-2334. http://dx.doi.org/10.1056/NEJMoa051908
|
[8]
|
P. E. Sax, R. Islam, R. P. Walensky, et al., “Should Resistance Testing Be Performed for Treatment-Naïve HIVInfected Patients? A Cost-Effectiveness Analysis,” Clinical Infectious Diseases, Vol. 41, No. 9, 2005, pp. 1316-1323. http://dx.doi.org/10.1086/496984
|
[9]
|
A. Mocroft, S. Vella, T. Benifield, et al., “Charging Patterns of Mortality Across Europe in Patients Infected with HIV-1,” Lancet, Vol. 352, No. 9142, 1998, pp. 1725-1730. http://dx.doi.org/10.1016/S0140-6736(98)03201-2
|
[10]
|
J. Marins, L. Jamal, S. Chen, et al., “Dramatic Improvement in Survival among Adult Brazilian AIDS Patients,” AIDS, Vol. 17, No. 11, 2003, pp. 1675-1682. http://dx.doi.org/10.1097/00002030-200307250-00012
|
[11]
|
J. Peterson and O. Obileye, “Access to Drugs for HIV/ AIDS and Related Opportunistic Infections in Nigeria,” POLICY Project, Nigeria, 2002.
|
[12]
|
O. Odutolu, B. A. Ahonsi, M. Gboun and O. M. Jolayemi, “The National Response to HIV/AIDS,” In: O. Adeyi, P. H. Kanki, O. Odutolu and J. A. Idoko, Eds., AIDS in Nigeria: “A Nation on a Threshold”, Harvard University Press, Cambridge, 2006, pp. 241-279.
|
[13]
|
C. Wallis, M. Papthanasopoulos, M. Fox, et al., “Lows Rate of Nucleoside Reverse Transcriptase Inhibitor (NRTI) Resistant Detected in a Well Monitored Cohort in South Africa Accessing Antiretroviral Therapy,” Antiviral Therapy, Vol. 17, No. 2, 2012, pp. 313-320. http://dx.doi.org/10.3851/IMP1985
|
[14]
|
V. C. Marconi, H. Sunpath, Z. G. Lu, M. Gordon, K. Koranteng-Apeagyei, J. Hampton, S. Carpentar, et al., “Prevalence of HIV-1 Drug Resistance After Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa,” Clinical Infectious Diseases, Vol. 46, No. 10, 2008, pp. 1589-1597. http://dx.doi.org/10.1086/587109
|
[15]
|
H. Hatano, P. Hunt, J. Weidler, et al., “Rate of Vira Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen,” Clinical Infectious Diseases, Vol. 43, No. 10, 2006, pp. 1329-1336. http://dx.doi.org/10.1086/508655
|
[16]
|
Nigeria’s HIV/AIDS Information Website, “Current HIV/ AIDS Statistics in Nigeria.” www.nigeriahivinfo.com
|
[17]
|
R. E. Nettles, T. L. Kieffer, R. P. Simmons, et al, “Genotypic Resistant in HIV-1-infcted Patients with Persistently Detectable Low Level Viremia While Receiving Highly Active Antiretroviral Therapy,” Clinical Infectious Diseases, Vol. 39, No. 7, 2004, pp. 1030-1037. http://dx.doi.org/10.1086/423388
|
[18]
|
S. Palmer, M. Kearney, F. Maldarelli, et al., “Multiple, Linked Human Immunodeficiency Virus Type Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis,” Journal of Clinical Microbiology, Vol. 43, No. 1, 2005, pp. 406-413. http://dx.doi.org/10.1128/JCM.43.1.406-413.2005
|
[19]
|
F. Doualla-Bell, T. Gaolathe, A. Avalos, et al., “Five Years Follow Up of Genotypic Resistance Patterns in HIV-1 Subtype C Infected Patients in Botswana after Failure of Thymidine Analogue-Based Regimens,” Journal of the International AIDS Society, Vol. 12, 2009, p. 25. http://dx.doi.org/10.1186/1758-2652-12-25
|
[20]
|
E. O. Idigbe, T. A. Adewole, G. Eisie, et al., “Management of HIV-1 Infection with a Combination of Nevirapine, Stavudine, and Lamivudine: A Preliminary Report on Nigerian Antiretroviral Program,” Journal of Acquired Immune Deficiency Syndromes, Vol. 40, No. 1, 2005, pp. 65-69. http://dx.doi.org/10.1097/01.qai.0000159516.39982.1b
|
[21]
|
J. E. Gallant, A. E. Rodriguez, W. G. Weinberg, et al., “Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV-Infected Antiretroviral-Naïve Subjects,” Journal of Infectious Diseases, Vol. 192, No. 11, 2005, pp. 921-930. http://dx.doi.org/10.1086/498069
|
[22]
|
World Health Organization, “HIV Drug Resistance Report,” 2012, pp. 3-78.
|
[23]
|
D. R. Kuritzkes, “Extending Antiretroviral Therapy to Resource-Poor Settings: Implications for Drug Resistance,” AIDS, Vol. 18, Suppl. 3, 2004, pp. S45-S48. http://dx.doi.org/10.1097/00002030-200406003-00009
|
[24]
|
J. M. Lang, J. Perriens, D. Kuritzkes and D. Zewdie, “What Policymakers Should Know about Drug Resistance and Adherence in the Context of Scaling-Up Treatment of HIV Infection,” AIDS, Vol. 18, Suppl. 13, 2004, pp. 569-574.
|
[25]
|
B. Chaplin, G. Eisen, J. Idoko, D. Onwujekwe, E. Idigbe, I. Adewole, W. Gashau, S. Meloni, A. D. Sarr, J. L. Sankalé, E. Ekong, R. L. Murphy and P. Kanki, “Impact of HIV Type 1 Subtype on Drug Resistance Mutations in Nigerian Patients Failing First-Line Therapy,” AIDS Research and Human Retroviruses, Vol. 27, No. 1, 2011, pp. 71-80. http://dx.doi.org/10.1089/aid.2010.0050
|
[26]
|
G. N. Odaibo, S. O. Ola, M. Landerz, U. Dietrich and D. O. Olaleye, “HIV-1 Drug Resistant Mutations in Chronically Infected Treatment Naive Individuals in the PreARV Era in Nigeria,” African Journal of Medicine & Medical Sciences, Vol. 41, 2012, pp. 61-63.
|
[27]
|
A. M. J. Wensing, D. A. van de Vijver, G. Angarano, et al., “Prevalence of Drug-Resistance HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management,” Journal of Infectious Diseases, Vol. 192, No. 6, 2005, pp. 958-966. http://dx.doi.org/10.1086/432916
|
[28]
|
D. Paraskevis, E. Magiokinis, A. Katsoulidou, et al., “Prevalence of Resistance-Associated Mutations in Newly Diagnosed HIV-1 Patients in Greece,” Virus Research, Vol. 112, No. 1, 2005, pp. 115-122. http://dx.doi.org/10.1016/j.virusres.2005.03.004
|
[29]
|
S. J. Litle, S. Holte, J. P. Routy, et al., “Antiretroviral-Drug Resistance among Patients Recently Infected with HIV,” New England Journal of Medicine, Vol. 347, 2002, pp. 385-394. http://dx.doi.org/10.1056/NEJMoa013552
|
[30]
|
R. L. Hamers, K. C. Sigaloff, A. M. Wensing, L. C. Wallis, C. KItyo, M. Siwale, K. Mandaliya, et al., “Patterns of HIV-1 Drug Resistance after First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies,” Clinical Infectious Diseases, Vol. 54, No. 11, 2012, pp. 1660-1669.
|
[31]
|
S. Jallow, A. Alabi, R. Sarge-Njie, K. Peterson, H. Whittle, et al., “Virological Response to Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency Virus Type 2 (HIV-2) and in Patients Dually Infected with HIV-1 and HIV-2 in the Gambia and Emergence of Drug Resistant Variants,” Journal of Clinical Microbiology, Vol. 47, No. 7, 2009, pp. 2200-2208. http://dx.doi.org/10.1128/JCM.01654-08
|
[32]
|
E. A. Abar, A. Jlizi, Y. H. Darar, et al., “HIV-1 Drug Resistance Genotyping from Antiretroviral Therapy (ART) Na?ve and First-Line Treatment Failures in Djiboutian Patients,” Diagnostic Pathology, Vol. 7, 2012, p. 138. http://dx.doi.org/10.1186/1746-1596-7-138
|
[33]
|
V. Novitsky, C. W. Wester, V. DeGruttola, et al., “The Reverse Transcriptate 67N 70R 215Y Genptype Is the Predominant TAM; Athway Associated with Virologic Failure among HIV Type 1C-Infected Adults Treated with ZDV/ddl-Containing HAART in Southern Africa,” AIDS Research and Human Retroviruses, Vol. 23, 2007, pp. 868-878. http://dx.doi.org/10.1089/aid.2006.0298
|
[34]
|
J. Liu, J. Yue, S. Wu and Y. Yan, “Polymorphisms and Drug Resistance Analysis of HIV-1 CRF01_AE Strains Circuiting in Fujian Province, China,” Archives of Virology, Vol. 152, No. 10, 2007, pp. 1799-1805. http://dx.doi.org/10.1007/s00705-007-1019-9
|
[35]
|
UK Group on Transmitted HIV Drug Resistance, “Time Trends in Primary Resistance HIV Drugs in the United Kingdom: Multicenter Observational Study,” British Medical Journal, Vol. 331, No. 7529, 2005, pp. 1368-1373. http://dx.doi.org/10.1136/bmj.38665.534595.55
|
[36]
|
N. A. Ingole, S. M. Kukreja and P.-R. Mehata, “Role of HIV-1 Viral Load in Initiating Antiviral Therapy,” World Journal of AIDS, Vol. 1, No. 4, 2011, pp. 149-154. http://dx.doi.org/10.4236/wja.2011.14022
|
[37]
|
WHO, “Clinical and Laboratory Monitoring of Antiretroviral Therapy in Resource-Limited and Unlimited Settings,” HIV/AIDS Antiretroviral Newsletter, No. 4, 2000, pp. 1-4.
|
[38]
|
S. P. Eholie, C. C. T. N’Dour, M. Cisse, E. Bissagnene and P. M. Girad, “Observance of Antiretroviral Treatments African Specificities,” Médecine et Maladies Infectieuses, Vol. 36, 2006, pp. 443-448.
|
[39]
|
B. Shah, L. Walshe, D. G. Saple, et al., “Adherence to Antiretroviral Therapy and Virologic Suppression among HIV-Infected Persons Receiving Care in Private Clinics in Mumbai, India,” Clinical Infectious Diseases, Vol. 44, No. 9, 2007, pp. 1235-1244. http://dx.doi.org/10.1086/513429
|
[40]
|
A. M. Geretti, C. Smith, A. Haberl, et al., “Determinants of Virological Failure after Successful Viral Load Suppression in First-Line Highly Active Antiretroviral Therapy,” Antiviral Therapy, Vol. 13, No. 7, 2008, pp. 927-936.
|
[41]
|
M. A. Chesney, J. Ickovics, F. M. Hecht, et al., “Adherence: A Necessity of Successful HIV Combination Therapy,” AIDS, Vol. 13, Suppl. A, 1999, pp. S271-S278.
|
[42]
|
A. J. Leigh Brown, S. D. Frost, W. C. Matthews, et al., “Transmission Fitness of Drug-Resistant Human Immunodeficiency Virus and the Prevalence of Resistance in the Antiretroviral-Treated Population,” Journal of Infectious Diseases, Vol. 187, No. 4, 2003, pp. 683-686. http://dx.doi.org/10.1086/367989
|
[43]
|
A. Fibrian, R. Wisaksana, A. Indrati, Y. Hartantri, et al., “Virology Failure and Drug Resistance during First Line Antiretroviral Treatment in Indolnesia,” Journal of Medical Virology, Vol. 85, No. 8, 2013, pp. 1394-1401. http://dx.doi.org/10.1002/jmv.23606
|
[44]
|
M. Vidya, S. Saravana, S. Uma, N. Kumarasamy, et al., “Genotypic HIV Type 1 Drug Resistance among Patients with Immunological Failure to First Line Antiretroviral Therapy on South India,” Antiviral Therapy, Vol. 14, No. 7, 2009, pp. 1005-1009. http://dx.doi.org/10.3851/IMP1411
|
[45]
|
“Stanford HIV Drug Resistance Database,” 2013. http//hivdb.stanford.edu/pages/drugSummaries.html
|
[46]
|
A. M. Geretti, “Clinical Implication of HIV Drug Resistance to Nucleoside Reverse Transcriptase Inhibitors,” AIDS Reviews, Vol. 8, No. 4, 2006, pp. 210-220.
|
[47]
|
V. A. Johnson, C. Vincent, H. F. Gunthard, P. Roger, P. Deenan, S. Robert, A. M. Wensing and D. D. Richman, “2011 Update of the Drug Resistance Mutation in HIV1,” Topics in Antiviral Medicine, Vol. 19, No. 4, 2011, pp. 156-164.
|
[48]
|
E. P. Coakley, J. M. Gills and S. M. Hammer, “Phenotypic and Gonotypicrersistance Pattern of HIV-1 Isolate Derived from Individuals Treated with Diagnosing and Stavudine,” AIDS, Vol. 14, 2002, pp. F9-F15. http://dx.doi.org/10.1097/00002030-200001280-00002
|
[49]
|
R. K. Gupta, A. Hill, A. W. Sawyer, et al., “Virological Monitoring and Resistant to First-Line Highly Active Antiretroviral Therapy in Adults Infected with HIV-1 Treated under WHO Guidelines: A Systematic Review and Mental Analysis,” Lancet Infectious Diseases, Vol. 9, 2009, pp. 409-417. http://dx.doi.org/10.1016/S1473-3099(09)70136-7
|